Pharmaceutical Raw Materials

Terazosin hydrochloride is a long-term selective drug α 1 receptor blocker is a derivative of quinazoline. By reducing the smooth muscle tension at the outlet of bladder, it can relieve dysuria caused by smooth muscle tension in benign prostatic hyperplasia. Terazosin hydrochloride can reduce blood pressure and maintain normal cardiac output. It can improve the metabolic disorders of blood lipids, blood glucose, blood uric acid and male sexual dysfunction. It is suitable for the treatment of hypertension and congestive heart failure. It can also be used for prostate hypertrophy. The treatment of mild and moderate benign prostatic hyperplasia caused by frequent micturition, urgency, nocturia increase, small urine volume, acute and chronic urinary incontinence and other stimulating symptoms, at the same time, it can improve the micturition hesitation, intermittent urine line, terminal drip urine, thin and weak urine line, incomplete micturition and so on. Treatment of chronic, non bacterial prostatitis and prostatitis * can also be used for female bladder neck obstruction and colon surgery before removal of urethral catheter, which can prevent acute urinary retention.

Glyclopyramide is a second-generation sulfonylurea with antihyperglycemic activity. Compared to first-generation compounds and like other second-generation compounds, glyclopyramide works more effectively with fewer side effects. This agent has a relatively short half-life of 4.0 hours and is excreted mainly by the kidneys.

Olpadronic acid (INN; salt form olpadronate) is a bisphosphonate.

Safotibant (INN) also known by the research code LF22-0542 is a non-peptide bradykinin B1 antagonist. It displayed binding Ki values of 0.35 and 6.5 nM at cloned human and mouse B1 receptors, respectively, while having no affinity for either human, mouse, or rat B2 receptors at concentrations up to 10 μM. This means that LF22-0542 is at least 4000 times selective for the B1 receptor over the B2 receptor. Systemic administration of LF22-0542 inhibited acute pain induced by acetic acid, formalin, and a hot plate. It also reversed acute inflammatory pain induced by carrageenan, and persistent inflammatory pain induced by CFA. In a neuropathic pain model, LF22-0542 reversed the thermal hyperalgesia, but not the mechanical hyperalgesia.

Fluorodeoxyglucose is a fluoro derivative of 2-deoxyglucose. Its complete chemical name is 2-fluoro-2-deoxy-D-glucose, usually referred to as 18F-FDG or FDG. FDG is most commonly used in medical imaging equipment of positron emission tomography (PET): Fluorine in FDG molecules is fluorine-18 (fluorine-18, F-18, 18F, 18 fluorine), which belongs to positron emission radioisotope, so it becomes 18F-FDG (fluorine - [18F] deoxyglucose). After injecting FDG into the patient (patient, patient), the PET scanner can construct an image reflecting the distribution of FDG in the body. Then, the nuclear medicine physician or radiologist evaluates these images to make a diagnosis of various medical health conditions.